{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:39Z","timestamp":1791245199903,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013003","name":"Universit\u00e0 degli Studi di Cagliari","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013003","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic Lymphocytic Leukemia (CLL) is well-known for increasing susceptibility to infections. Factors such as immune dysregulation, IGHV status, hypogammaglobulinemia, and patient comorbidity and treatment, contribute to higher infection rates and mortality. However, the impact of hypogammaglobulinemia on infection rates is controversial. We aimed to identify clinical and biological parameters linked to the risk of severe infectious events. Additionally, we set up a straightforward risk infection score to stratify CLL patients at diagnosis, thereby enabling the development of suitable infection prevention strategies. We retrospectively evaluated 210 unselected CLL patients diagnosed between 1988 and 2018. This evaluation encompassed demographics, Binet stage, immunoglobulin (Ig) levels, treatment history, comorbidities, and IGHV mutational status at diagnosis. The frequency and severity of infectious events were recorded. Analysis revealed that age, IGHV mutational status, Binet stage, and hypogammaglobulinemia were statistically associated with the Time to First Infection (TTFI) in univariate and multivariate analyses. Using hazard ratios from the multivariate analysis, we finally devised a risk scoring system that integrated age, IGHV mutational status, immunoglobulin levels, and Binet stage to stratify patients at diagnosis based on their specific infection risk. In our cohort, disease progression and infections were the leading cause of death. These findings pointed out the clinical need for a screening process strategic for defining infectious risk at the time of CLL diagnosis, with a significant enhancement in the clinical management of these patients.<\/jats:p>","DOI":"10.1007\/s00277-024-05625-y","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T05:02:13Z","timestamp":1705554133000},"page":"1655-1664","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prediction of severe infections in chronic lymphocytic leukemia: a simple risk score to stratify patients at diagnosis"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9792-9542","authenticated-orcid":false,"given":"Roberta","family":"Murru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9122-4258","authenticated-orcid":false,"given":"Andrea","family":"Galitzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3676-3240","authenticated-orcid":false,"given":"Luca","family":"Barabino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6436-2156","authenticated-orcid":false,"given":"Roberta","family":"Presicci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8247-583X","authenticated-orcid":false,"given":"Giorgio","family":"La Nasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6585-5187","authenticated-orcid":false,"given":"Giovanni","family":"Caocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"5625_CR1","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.clml.2023.02.001","volume":"23","author":"E Gargiulo","year":"2023","unstructured":"Gargiulo E, Ribeiro EFO, Niemann CU (2023) SOHO State of the art updates and next questions | infections in chronic lymphocytic leukemia patients: risks and management. Clin Lymphoma Myeloma Leuk 23:322\u2013332. https:\/\/doi.org\/10.1016\/j.clml.2023.02.001","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5625_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/17474086.2018.1407645","volume":"11","author":"T Tadmor","year":"2018","unstructured":"Tadmor T, Welslau M, Hus I (2018) A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia. Expert Rev Hematol 11:57\u201370. https:\/\/doi.org\/10.1080\/17474086.2018.1407645","journal-title":"Expert Rev Hematol"},{"key":"5625_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.blre.2018.03.004","volume":"32","author":"T Hilal","year":"2018","unstructured":"Hilal T, Gea-Banacloche JC, Leis JF (2018) Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: linking mechanisms with infections. Blood Rev 32:387\u2013399. https:\/\/doi.org\/10.1016\/j.blre.2018.03.004","journal-title":"Blood Rev"},{"key":"5625_CR4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/bjh.14785","volume":"178","author":"P Strati","year":"2017","unstructured":"Strati P, Parikh SA, Chaffee KG et al (2017) Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol 178:394\u2013402. https:\/\/doi.org\/10.1111\/bjh.14785","journal-title":"Br J Haematol"},{"key":"5625_CR5","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41375-021-01156-x","volume":"35","author":"EC Rotbain","year":"2021","unstructured":"Rotbain EC, Niemann CU, Rostgaard K et al (2021) Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death. Leukemia 35:2570\u20132580. https:\/\/doi.org\/10.1038\/s41375-021-01156-x","journal-title":"Leukemia"},{"key":"5625_CR6","doi-asserted-by":"publisher","first-page":"e329","DOI":"10.3324\/haematol.2018.196543","volume":"103","author":"KR Crassini","year":"2018","unstructured":"Crassini KR, Best OG, Mulligan SP (2018) Immune failure, infection and survival in chronic lymphocytic leukemia. Haematologica 103:e329\u2013e329. https:\/\/doi.org\/10.3324\/haematol.2018.196543","journal-title":"Haematologica"},{"key":"5625_CR7","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.3324\/haematol.2018.197889","volume":"103","author":"MA Andersen","year":"2018","unstructured":"Andersen MA, Niemann CU (2018) Immune failure, infection and survival in chronic lymphocytic leukemia in Denmark. Haematologica 103:e330\u2013e330. https:\/\/doi.org\/10.3324\/haematol.2018.197889","journal-title":"Haematologica"},{"key":"5625_CR8","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1159\/000514071","volume":"144","author":"P Langerbeins","year":"2021","unstructured":"Langerbeins P, Eichhorst B (2021) Immune Dysfunction in patients with chronic lymphocytic leukemia and challenges during COVID-19 pandemic. Acta Haematol 144:508\u2013518. https:\/\/doi.org\/10.1159\/000514071","journal-title":"Acta Haematol"},{"key":"5625_CR9","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1038\/s41375-021-01450-8","volume":"35","author":"T Chatzikonstantinou","year":"2021","unstructured":"Chatzikonstantinou T, Kapetanakis A, Scarf\u00f2 L et al (2021) COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia 35:3444\u20133454. https:\/\/doi.org\/10.1038\/s41375-021-01450-8","journal-title":"Leukemia"},{"key":"5625_CR10","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood.2021011568","volume":"137","author":"Y Herishanu","year":"2021","unstructured":"Herishanu Y, Avivi I, Aharon A et al (2021) Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood 137:3165\u20133173. https:\/\/doi.org\/10.1182\/blood.2021011568","journal-title":"Blood"},{"key":"5625_CR11","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.3390\/cancers15082266","volume":"15","author":"E Liatsou","year":"2023","unstructured":"Liatsou E, Ntanasis-Stathopoulos I, Lykos S et al (2023) Adult patients with Cancer have impaired humoral responses to complete and Booster COVID-19 vaccination, especially those with hematologic Cancer on active treatment: a systematic review and Meta-analysis. Cancers 15:2266. https:\/\/doi.org\/10.3390\/cancers15082266","journal-title":"Cancers"},{"key":"5625_CR12","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.3390\/vaccines10071162","volume":"10","author":"A Galitzia","year":"2022","unstructured":"Galitzia A, Barabino L, Murru R et al (2022) Patients with chronic lymphocytic leukemia have a very high risk of ineffective response to the BNT162b2 vaccine. Vaccines 10:1162. https:\/\/doi.org\/10.3390\/vaccines10071162","journal-title":"Vaccines"},{"key":"5625_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","volume":"126","author":"F Forconi","year":"2015","unstructured":"Forconi F, Moss P (2015) Perturbation of the normal immune system in patients with CLL. Blood 126:573\u2013581. https:\/\/doi.org\/10.1182\/blood-2015-03-567388","journal-title":"Blood"},{"key":"5625_CR14","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.3390\/cancers13153856","volume":"13","author":"C Vitale","year":"2021","unstructured":"Vitale C, Boccellato E, Comba L et al (2021) Impact of Immune parameters and Immune dysfunctions on the prognosis of patients with chronic lymphocytic leukemia. Cancers 13:3856. https:\/\/doi.org\/10.3390\/cancers13153856","journal-title":"Cancers"},{"key":"5625_CR15","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1002\/cncr.29438","volume":"121","author":"SA Parikh","year":"2015","unstructured":"Parikh SA, Leis JF, Chaffee KG et al (2015) Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes: hypogammaglobulinemia in CLL. Cancer 121:2883\u20132891. https:\/\/doi.org\/10.1002\/cncr.29438","journal-title":"Cancer"},{"key":"5625_CR16","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.3109\/10428194.2016.1142082","volume":"57","author":"MA Andersen","year":"2016","unstructured":"Andersen MA, Vojdeman FJ, Andersen MK et al (2016) Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death. Leuk Lymphoma 57:1592\u20131599. https:\/\/doi.org\/10.3109\/10428194.2016.1142082","journal-title":"Leuk Lymphoma"},{"key":"5625_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3109\/10428194.2012.706285","volume":"54","author":"JA Freeman","year":"2013","unstructured":"Freeman JA, Crassini KR, Best OG et al (2013) Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leuk Lymphoma 54:99\u2013104. https:\/\/doi.org\/10.3109\/10428194.2012.706285","journal-title":"Leuk Lymphoma"},{"key":"5625_CR18","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1182\/bloodadvances.2018026591","volume":"3","author":"G Ishdorj","year":"2019","unstructured":"Ishdorj G, Streu E, Lambert P et al (2019) IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia. Blood Adv 3:2188\u20132198. https:\/\/doi.org\/10.1182\/bloodadvances.2018026591","journal-title":"Blood Adv"},{"key":"5625_CR19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/jha2.95","volume":"1","author":"N Singh","year":"2020","unstructured":"Singh N, Mott SL, Sutamtewagul G et al (2020) Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients. eJHaem 1:537\u2013544. https:\/\/doi.org\/10.1002\/jha2.95","journal-title":"eJHaem"},{"key":"5625_CR20","doi-asserted-by":"publisher","first-page":"e515","DOI":"10.3324\/haematol.2015.126763","volume":"100","author":"A Visentin","year":"2015","unstructured":"Visentin A, Compagno N, Cinetto F et al (2015) Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy. Haematologica 100:e515\u2013e518. https:\/\/doi.org\/10.3324\/haematol.2015.126763","journal-title":"Haematologica"},{"key":"5625_CR21","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/cncr.22094","volume":"107","author":"S Francis","year":"2006","unstructured":"Francis S, Karanth M, Pratt G et al (2006) The effect of immunoglobulinVH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer 107:1023\u20131033. https:\/\/doi.org\/10.1002\/cncr.22094","journal-title":"Cancer"},{"key":"5625_CR22","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/j.1365-2141.2008.07050.x","volume":"141","author":"D Rossi","year":"2008","unstructured":"Rossi D, De Paoli L, Rossi FM et al (2008) Early stage chronic lymphocytic leukaemia carrying unmutated IGHV genes is at risk of recurrent infections during watch and wait. Br J Haematol 141:734\u2013736. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07050.x","journal-title":"Br J Haematol"},{"key":"5625_CR23","doi-asserted-by":"publisher","first-page":"e300","DOI":"10.3324\/haematol.2017.182006","volume":"103","author":"MA Andersen","year":"2018","unstructured":"Andersen MA, Eriksen CT, Brieghel C et al (2018) Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study. Haematologica 103:e300\u2013e303. https:\/\/doi.org\/10.3324\/haematol.2017.182006","journal-title":"Haematologica"},{"key":"5625_CR24","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1046\/j.1365-2141.2003.04497.x","volume":"122","author":"M Hensel","year":"2003","unstructured":"Hensel M, Kornacker M, Yammeni S et al (2003) Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia: infections in CLL. Br J Haematol 122:600\u2013606. https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04497.x","journal-title":"Br J Haematol"},{"key":"5625_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.leukres.2017.02.011","volume":"57","author":"FR Mauro","year":"2017","unstructured":"Mauro FR, Morabito F, Vincelli ID et al (2017) Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage a chronic lymphocytic leukemia. Leuk Res 57:65\u201371. https:\/\/doi.org\/10.1016\/j.leukres.2017.02.011","journal-title":"Leuk Res"},{"key":"5625_CR26","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.blre.2018.04.007","volume":"32","author":"BW Teh","year":"2018","unstructured":"Teh BW, Tam CS, Handunnetti S et al (2018) Infections in patients with chronic lymphocytic leukaemia: mitigating risk in the era of targeted therapies. Blood Rev 32:499\u2013507. https:\/\/doi.org\/10.1016\/j.blre.2018.04.007","journal-title":"Blood Rev"},{"key":"5625_CR27","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.3390\/cells9112398","volume":"9","author":"E Grywalska","year":"2020","unstructured":"Grywalska E, Zaborek M, \u0141yczba J et al (2020) Chronic lymphocytic Leukemia-Induced Humoral Immunosuppression: a systematic review. Cells 9:2398. https:\/\/doi.org\/10.3390\/cells9112398","journal-title":"Cells"},{"key":"5625_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","volume":"32","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Robak T, Montserrat E et al (2021) Chronic lymphocytic leukaemia: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 32:23\u201333. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.019","journal-title":"Ann Oncol"},{"key":"5625_CR29","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41467-019-14225-8","volume":"11","author":"R Agius","year":"2020","unstructured":"Agius R, Brieghel C, Andersen MA et al (2020) Machine learning can identify newly diagnosed patients with CLL at high risk of infection. Nat Commun 11:363. https:\/\/doi.org\/10.1038\/s41467-019-14225-8","journal-title":"Nat Commun"},{"key":"5625_CR30","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.3390\/cancers13133240","volume":"13","author":"FR Mauro","year":"2021","unstructured":"Mauro FR, Giannarelli D, Visentin A et al (2021) Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with Ibrutinib. Cancers 13:3240. https:\/\/doi.org\/10.3390\/cancers13133240","journal-title":"Cancers"},{"key":"5625_CR31","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D et al (2018) iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131:2745\u20132760. https:\/\/doi.org\/10.1182\/blood-2017-09-806398","journal-title":"Blood"},{"key":"5625_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejca.2016.11.020","volume":"72","author":"A Visentin","year":"2017","unstructured":"Visentin A, Imbergamo S, Gurrieri C et al (2017) Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients. Eur J Cancer 72:103\u2013111. https:\/\/doi.org\/10.1016\/j.ejca.2016.11.020","journal-title":"Eur J Cancer"},{"key":"5625_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/ejh.12290","volume":"93","author":"L Shvidel","year":"2014","unstructured":"Shvidel L, Tadmor T, Braester A et al (2014) Serum immunoglobulin levels at diagnosis have no prognostic significance in stage a chronic lymphocytic leukemia: a study of 1113 cases from the Israeli CLL Study Group. Eur J Haematol 93:29\u201333. https:\/\/doi.org\/10.1111\/ejh.12290","journal-title":"Eur J Haematol"},{"key":"5625_CR34","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/bjh.16975","volume":"190","author":"A Corbingi","year":"2020","unstructured":"Corbingi A, Innocenti I, Tomasso A et al (2020) Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia. Br J Haematol 190:901\u2013908. https:\/\/doi.org\/10.1111\/bjh.16975","journal-title":"Br J Haematol"},{"key":"5625_CR35","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41375-018-0344-1","volume":"33","author":"G Reda","year":"2019","unstructured":"Reda G, Cassin R, Gentile M et al (2019) IgA Hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia. Leukemia 33:1519\u20131522. https:\/\/doi.org\/10.1038\/s41375-018-0344-1","journal-title":"Leukemia"},{"key":"5625_CR36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s13046-021-02115-1","volume":"40","author":"C Moreno","year":"2021","unstructured":"Moreno C, Mu\u00f1oz C, Terol MJ et al (2021) Restoration of the immune function as a complementary strategy to treat chronic lymphocytic leukemia effectively. J Exp Clin Cancer Res 40:321. https:\/\/doi.org\/10.1186\/s13046-021-02115-1","journal-title":"J Exp Clin Cancer Res"},{"key":"5625_CR37","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","volume":"126","author":"C Sun","year":"2015","unstructured":"Sun C, Tian X, Lee YS et al (2015) Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood 126:2213\u20132219. https:\/\/doi.org\/10.1182\/blood-2015-04-639203","journal-title":"Blood"},{"key":"5625_CR38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1182\/blood.2023020554","volume":"143","author":"D Papazoglou","year":"2024","unstructured":"Papazoglou D, Wang XV, Shanafelt TD et al (2024) Ibrutinib-based therapy reinvigorates CD8\u2009+\u2009T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial. Blood 143:57\u201363. https:\/\/doi.org\/10.1182\/blood.2023020554","journal-title":"Blood"},{"key":"5625_CR39","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.1182\/bloodadvances.2023010236","volume":"7","author":"C Moreno","year":"2023","unstructured":"Moreno C, Solman IG, Tam CS et al (2023) Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study. Blood Adv 7:5294\u20135303. https:\/\/doi.org\/10.1182\/bloodadvances.2023010236","journal-title":"Blood Adv"},{"key":"5625_CR40","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1182\/blood-2019-121907","volume":"134","author":"C Da Cunha-Bang","year":"2019","unstructured":"Da Cunha-Bang C, Agius R, Kater AP et al (2019) PreVent-ACaLL short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and\/or early treatment, who do not fulfil IWCLL treatment criteria for treatment. A randomized study with extensive immune phenotyping. Blood 134:4304\u20134304. https:\/\/doi.org\/10.1182\/blood-2019-121907","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05625-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05625-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05625-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T06:04:03Z","timestamp":1712901843000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05625-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["5625"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05625-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]},"assertion":[{"value":"12 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patient data were retrospectively collected in accordance with the ethical standards of the institutional and\/or national research committee and with the 1975 Guidelines of the Declaration of Helsinki. All patients provided informed consent for the processing of their personal data and retrospective data collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}